Department of Internal Medicine, PGIMER, Chandigarh, India.
Department of Haematology, PGIMER, Chandigarh, India.
Br J Haematol. 2020 May;189(4):772-776. doi: 10.1111/bjh.16412. Epub 2020 Feb 3.
Mesenchymal stromal cells (MSCs) demonstrate the properties of self-renewal, multipotentiality, and immunosuppression, which are responsible for their widespread clinical applications in tissue repair and regeneration. MSCs have been isolated from bone marrow, adipose tissue, and cord blood using culture in specialised media. Their presence in peripheral blood (PB) is debatable. We studied the presence of MSCs at baseline (PB) and following mobilisation with growth factors [PB and apheresis product (AP)] in patients undergoing autologous stem cell transplantation and healthy donors using flow cytometry. We conclude that both mobilised PB and AP are potential sources of MSCs. Given their small numbers in PB/AP, clinical use is feasible following ex-vivo expansion. Variables affecting the presence of MSCs in PB and AP are also discussed.
间充质基质细胞 (MSCs) 表现出自体更新、多能性和免疫抑制的特性，这使其在组织修复和再生的广泛临床应用中具有重要意义。MSCs 已经从骨髓、脂肪组织和脐血中通过专门的培养基培养分离出来。它们在外周血（PB）中的存在是有争议的。我们使用流式细胞术研究了接受自体干细胞移植的患者和健康供体在基线（PB）时以及使用生长因子动员后（PB 和单采产品（AP））MSC 的存在情况。我们的结论是，动员后的 PB 和 AP 都是 MSC 的潜在来源。由于它们在 PB/AP 中的数量较少，因此在体外扩增后可用于临床。还讨论了影响 PB 和 AP 中 MSC 存在的变量。
